Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 20/20 | 1.00 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.81 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.74 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.74 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.74 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30255314 | 1.00 | ADORA3 (1.00) | ADORA3ADORA2ASLC6A2SLC6A3KCNH2 | |
| SCHEMBL16774326 | 1.00 | ADORA3 (1.00) | ADORA3ADORA2ASLC6A2SLC6A3KCNH2 | |
| SCHEMBL30255415 | 0.91 | ADORA3 (1.00) | ADORA3ADORA2ASLC6A2SLC6A3KCNH2 | |
| SCHEMBL16774160 | 0.91 | ADORA3 (1.00) | ADORA3ADORA2ASLC6A2SLC6A3KCNH2 | |
| SCHEMBL10322598 | 0.90 | ADORA3 (1.00) | ADORA3ADORA2ASLC6A2SLC6A3KCNH2 | |
| SCHEMBL16361552 | 0.90 | ADORA3 (1.00) | ADORA3ADORA2ASLC6A2SLC6A3KCNH2 | |
| SCHEMBL16361546 | 0.89 | ADORA3 (1.00) | ADORA3ADORA2ASLC6A2SLC6A3KCNH2 | |
| SCHEMBL10322961 | 0.89 | ADORA3 (1.00) | ADORA3ADORA2ASLC6A2SLC6A3KCNH2 | |
| SCHEMBL10322659 | 0.89 | ADORA3 (1.00) | ADORA3ADORA2ASLC6A2SLC6A3KCNH2 | |
| SCHEMBL16361550 | 0.89 | ADORA3 (1.00) | ADORA3ADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10577368-B2 | A3 adenosine receptor agonists | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2020-03-03 | — | — | US | disclosed |
| US-9963450-B2 | A3 adenosine receptor agonists | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2018-05-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10577368-B2 | A3 adenosine receptor agonists | ADORA3, ADORA2B, ADORA1 | ADORA3 1/4885ADORA2A 4/4885SLC6A2 723/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.